Fig. 1

SF-36 domain scores at baseline and week 52. SF-36 domain scores are shown for the TCZ-weekly group compared with the placebo-26-week taper (a) and compared with the placebo-52-week taper (b) groups. Values shown in parentheses are the numbers of patients. *p < 0.01 TCZ-QW + Pred-26 vs PBO + Pred group. A/G age/gender, BL baseline, BP bodily pain, GH general health, MH mental health, PBO placebo, PF physical function, Pred-26 26-week prednisone taper, Pred-52 52-week prednisone taper, QW every week, RE role emotional, RP role physical, SF social function, SF-36 36-Item Short-Form Health Survey, TCZ tocilizumab, VT vitality